search
Back to results

The Effect of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability (Promi2)

Primary Purpose

Migraine

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
EcologicBarrier
Placebo
Sponsored by
Wageningen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Migraine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects confirm to have migraine characterized by :

    • Recurrent attacks of moderate to severe headaches, often one-sided and pounding, often with nausea and/or vomiting, aggravated by physical activity
    • Sensitivity for light or sounds is possible but not exclusive.
    • Attacks last for 4 to 72 hours.
  • Self-reported frequency of migraine attacks (or days) at least 4 per month
  • Fairly predictable/stable pattern of migraine attacks (frequency, duration, intensity)
  • Age ≥ 18 years
  • Good overall health (self-reported in medical questionnaire)

Exclusion Criteria:

  • Migraine patients who suffer from chronic daily migraine/headaches
  • Migraine patients who suffer from medication-dependent headaches
  • Subjects who suffer from cluster headache or tension-type headaches
  • Subjects who used antibiotics up to two months before the start of the study
  • Subjects who are unwilling to stop taking probiotics other than study products
  • Patients with a chronic use of non steroid anti inflammatory drugs (because of increased gut permeability)
  • Patients with inflammatory bowel diseases (because of increased gut permeability)
  • Pregnancy or lactation (because of their possible effect on migraine incidence)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Probiotics

    Placebo

    Arm Description

    EcologicBarrier, 5x10E9 cfu/day

    carrier material of Ecologic Barrier, not containing bacterial strains

    Outcomes

    Primary Outcome Measures

    Frequency of migraine attacks

    Secondary Outcome Measures

    Intestinal permeability
    Lactulose/mannitol in urine, zonulin in serum
    Inflammation markers.
    pro-inflammatory cytokines in serum

    Full Information

    First Posted
    January 9, 2015
    Last Updated
    January 14, 2015
    Sponsor
    Wageningen University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02342262
    Brief Title
    The Effect of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability
    Acronym
    Promi2
    Official Title
    The Effects of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability. A Placebo-controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2015
    Overall Recruitment Status
    Unknown status
    Study Start Date
    August 2014 (undefined)
    Primary Completion Date
    August 2015 (Anticipated)
    Study Completion Date
    October 2015 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Wageningen University

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    RATIONALE: The prevalence of migraine is higher in patients with various intestinal diseases. An explanation could be that migraine is caused by a 'leaky gut': an increased intestinal permeability that allows food particles to pass the gastrointestinal wall. Probiotics may be able to improve intestinal barrier function. OBJECTIVE: To test whether probiotics, as adjuvant therapy, can reduce incidence and severity of migraine attacks by reducing intestinal permeability. STUDY DESIGN: 12-week placebo-controlled randomized double-blind intervention with selected probiotics. STUDY POPULATION: Adults who experience at least 4 migraine attacks per month. INTERVENTION: Subjects will receive either one daily dose of 2 g of Ecologic® Barrier or 2 grams of the placebo, containing only the carrier material (both provided by Winclove Probiotics). MAIN STUDY PARAMETERS/ENDPOINTS: Incidence and severity of migraine attacks, measured by diaries and validated headache questionnaires will be measured at baseline and after 4, 8, and 12 weeks of probiotic/placebo administration. Secondary, intestinal permeability will be measured by the lactulose/mannitol absorption test in urine (screening, baseline and 12 weeks) and by fecal zonulin (baseline, 4, 8, and 12 weeks). Inflammation will be assessed from blood C-reactive protein and cytokine concentrations (baseline, 4, 8, and 12 weeks). Fecal samples will also be used for microbial analysis.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Migraine

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    80 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Probiotics
    Arm Type
    Experimental
    Arm Description
    EcologicBarrier, 5x10E9 cfu/day
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    carrier material of Ecologic Barrier, not containing bacterial strains
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    EcologicBarrier
    Intervention Description
    multispecies probiotic product, 2x10-9 cfu/gram
    Intervention Type
    Other
    Intervention Name(s)
    Placebo
    Intervention Description
    similar appearance as the probiotic product, but without bacteria
    Primary Outcome Measure Information:
    Title
    Frequency of migraine attacks
    Time Frame
    12 weeks
    Secondary Outcome Measure Information:
    Title
    Intestinal permeability
    Description
    Lactulose/mannitol in urine, zonulin in serum
    Time Frame
    12 weeks
    Title
    Inflammation markers.
    Description
    pro-inflammatory cytokines in serum
    Time Frame
    12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subjects confirm to have migraine characterized by : Recurrent attacks of moderate to severe headaches, often one-sided and pounding, often with nausea and/or vomiting, aggravated by physical activity Sensitivity for light or sounds is possible but not exclusive. Attacks last for 4 to 72 hours. Self-reported frequency of migraine attacks (or days) at least 4 per month Fairly predictable/stable pattern of migraine attacks (frequency, duration, intensity) Age ≥ 18 years Good overall health (self-reported in medical questionnaire) Exclusion Criteria: Migraine patients who suffer from chronic daily migraine/headaches Migraine patients who suffer from medication-dependent headaches Subjects who suffer from cluster headache or tension-type headaches Subjects who used antibiotics up to two months before the start of the study Subjects who are unwilling to stop taking probiotics other than study products Patients with a chronic use of non steroid anti inflammatory drugs (because of increased gut permeability) Patients with inflammatory bowel diseases (because of increased gut permeability) Pregnancy or lactation (because of their possible effect on migraine incidence)
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Nicole De Roos, PhD
    Organizational Affiliation
    Wageningen UR
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    The Effect of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability

    We'll reach out to this number within 24 hrs